EISAI CO LTD (ESALF:OTCMKTS)

$26.175 1.175 (4.7%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 75

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed EISAI CO LTD (ESALF:OTCMKTS) News Sources

Is Nuvation Bio’s (NUVB) Expanding Taletrectinib Footprint Quietly Rewriting Its Global Oncology Narrative?

02-07-2026

yahoo.com

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

12-07-2026

yahoo.com

New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease

13-07-2026

yahoo.com

Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026

13-07-2026

yahoo.com

Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level?

13-07-2026

yahoo.com

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

13-07-2026

yahoo.com

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

14-07-2026

yahoo.com

Can Biogen Score Another Win In Alzheimer's Disease?

14-07-2026

yahoo.com

How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval

14-07-2026

yahoo.com

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

14-07-2026

yahoo.com

EISAI CO LTD (ESALF:OTCMKTS) Sentiment Trend

0 25 50 75 100 82 73 73 64 93 80 72 55 86 78 02-07-2026 12-07-2026 13-07-2026 14-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

EISAI CO LTD (ESALF:OTCMKTS) FAQs

toggle

What is the current price of EISAI CO LTD (ESALF:OTCMKTS)?

The current price of EISAI CO LTD (ESALF:OTCMKTS) is $26.175.


toggle

EISAI CO LTD (ESALF:OTCMKTS) absolute price change since previous trading day?

The absolute price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is $1.175.


toggle

EISAI CO LTD (ESALF:OTCMKTS) percentage price change since previous trading day?

The percentage price change of EISAI CO LTD (ESALF:OTCMKTS) since the previous trading day is 4.7%.


toggle

What is the most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS)?

The most recent average sentiment score for EISAI CO LTD (ESALF:OTCMKTS) is 75 out of 100.


toggle

What is the most recent average sentiment for EISAI CO LTD (ESALF:OTCMKTS)?

The most recent sentiment for EISAI CO LTD (ESALF:OTCMKTS) is .


SEC-8K** Filing Available For EISAI CO LTD (ESALF:OTCMKTS)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.